Tenax Therapeutics Inc (TENX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.90 (+2.15%), Market cap $0.33B, 52-week low–high $5.62 ~ $18.27.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North
Financial statements, price targets, institutional (13F) holdings and related news for Tenax Therapeutics Inc are updated in real time on BlackAll Trade.
Tenax Therapeutics Inc trades at $1.90 (+2.15%). Real-time quotes and charts are available on BlackAll Trade.
Tenax Therapeutics Inc has a market cap of about $0.33B.
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have